Lupin reported its performance for the fourth quarter ending March 31, 2014. These audited results were taken on record by the Board of Directors at a meeting in Mumbai recently. The net sales grew by 17.2 per cent to Rs 110,866 million during FY 2013-14, up from Rs 94,616 million, FY 2012-13. Net sales grew by 20.3 per cent to Rs 30,515 million during Q4 FY 2013-14, up from Rs 25,374 million in Q4 FY 2012-13.
Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) grew by 35.8 per cent Rs 31,193 million during FY 2013-14, up from Rs 22,977 million, FY 2012-13. EBITDA grew by 32.7 per cent to Rs 8,821 million during Q4 FY 2013-14, up from Rs 6,649 million in Q4 FY 2012-13.
Profit before tax (PBT) grew by 47.1 per cent to Rs 28,317 million during FY 2013-14, up from Rs 19,246 million, FY 2012-13. PBT grew by 52.2 per cent to Rs 7,956 million during Q4 FY 2013-14, up from Rs 5,226 million in Q4 FY 2012-13. Net profits grew by 39.7 per cent to Rs 18,364 million during FY2013-14, up from Rs 13,142 million, FY 2012-13.
Net profits grew by 35.5 per cent to Rs 5,530 million during Q4 FY 2013-14, up from Rs 4,081 million in Q4 FY 2012-13.
Nilesh Gupta, Managing Director, Lupin said “We have had another remarkable year fuelled by strong growth in key markets like the US, Europe, South Africa and in our API business. Importantly, we were able to improve operational efficiencies substantially. The year also marked our entry into high growth markets like Mexico and acquiring technology research capabilities that would help us address niche segments like complex injectables and inhalation.”
EP News Bureau– Mumbai
- Advertisement -
